Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes

Roy W. Beck; Carol J. Levy; Yogish C. Kudva; Keta Pandit; Thomas Blevins; Dan Raghinaru; Jordan E. Pinsker

doi:10.2337/cd23-0107

Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes

Roy W. Beck
, Carol J. Levy
, Yogish C. Kudva
, Keta Pandit
, Thomas Blevins
, Dan Raghinaru
, Jordan E. Pinsker

Icahn School of Medicine at Mount Sinai

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Original language	English
Pages (from-to)	547-549
Number of pages	3
Journal	Clinical Diabetes
Volume	42
Issue number	4
DOIs	https://doi.org/10.2337/cd23-0107
State	Published - Sep 2024

Access to Document

10.2337/cd23-0107

Cite this

@article{831b22c3ac8c4953a1c37e5936650731,

title = "Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes",

author = "Beck, \{Roy W.\} and Levy, \{Carol J.\} and Kudva, \{Yogish C.\} and Keta Pandit and Thomas Blevins and Dan Raghinaru and Pinsker, \{Jordan E.\}",

year = "2024",

month = sep,

doi = "10.2337/cd23-0107",

language = "English",

volume = "42",

pages = "547--549",

journal = "Clinical Diabetes",

issn = "0891-8929",

publisher = "American Diabetes Association Inc.",

number = "4",

}

TY - JOUR

T1 - Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes

AU - Beck, Roy W.

AU - Levy, Carol J.

AU - Kudva, Yogish C.

AU - Pandit, Keta

AU - Blevins, Thomas

AU - Raghinaru, Dan

AU - Pinsker, Jordan E.

PY - 2024/9

Y1 - 2024/9

UR - https://www.scopus.com/pages/publications/105002162106

U2 - 10.2337/cd23-0107

DO - 10.2337/cd23-0107

M3 - Comment/debate

AN - SCOPUS:105002162106

SN - 0891-8929

VL - 42

SP - 547

EP - 549

JO - Clinical Diabetes

JF - Clinical Diabetes

IS - 4

ER -